Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16428672 | 1.00 | CYP1A2 (0.32) | CYP1A2POLB | |
| SCHEMBL16428671 | 1.00 | CYP1A2 (0.32) | CYP1A2POLB | |
| SCHEMBL23364787 | 0.94 | CYP1A2 (0.36) | CYP1A2POLB | |
| SCHEMBL23364786 | 0.94 | CYP1A2 (0.36) | CYP1A2POLB | |
| SCHEMBL12990831 | 0.85 | — | — | |
| SCHEMBL15941234 | 0.75 | CYP1A2 (0.33) | CYP1A2POLB | |
| SCHEMBL15941345 | 0.75 | CYP1A2 (0.33) | CYP1A2POLB | |
| SCHEMBL16267236 | 0.73 | CES2 (0.31) | — | |
| SCHEMBL16267235 | 0.73 | CES2 (0.31) | — | |
| SCHEMBL16267237 | 0.73 | CES2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038574-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | CYP1A2 4463/4885POLB 1818/4885 |
| US-10040749-B2 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, PDE6C | CYP1A2 4463/4885POLB 1818/4885 |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | CYP1A2 4463/4885POLB 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.